SEC Form 4 · accession 0001209191-18-023729

bluebird bio, Inc. · BLUE

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Scientific Officer

Period of report

Apr 2, 2018

Accepted (ET)

Apr 4, 2018 · 4:50 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001293971

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Apr 2, 2018	M	1,250	$50.51	A	31,522	D
Common Stock^F2	Apr 2, 2018	S	1,250	$167.642	D	30,272	D
Common Stock^F3	Apr 2, 2018	S	300	$169.0183	D	29,972	D
Common Stock	Apr 2, 2018	S	700	$170.50	D	29,272	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F4	$50.51	Apr 2, 2018	M	1,250	D	—	Mar 1, 2026	Common Stock	1,250	17,000	D

F1The sales reported in the Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on March 17, 2017.
F2The range in prices for the transaction reported on this line was $167.30 to $168.20. The average weighted price was $167.6420. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3The range in prices for the transaction reported on this line was $169.00 to $169.05. The average weighted price was $169.0183. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price
F4This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2017 and in 36 equal monthly installments thereafter.